Interleukin-6 inhibitors (tocilizumab and sarilumab) for critically ill patients with COVID-19 pneumonia (adults)
NHS trusts / health boards are recommended to consider prescribing either tocilizumab or sarilumab to hospitalised patients being treated with non-invasive ventilation (high-flow nasal oxygen therapy or continuous positive airway pressure ventilation) or invasive mechanical
Source:
Medicines and Healthcare products Regulatory Agency
SPS commentary:
This alert is supported by UK Interim Clinical Commissioning Policies for tocilizumab and sarilumab which describe the criteria for use and exclusion criteria in detail.